KRAS and non-small cell lung carcinoma: Recently, the KRAS inhibitors Sotorasib (AMG 510/Lumakras) and Adagrasib (MRTX849/Krazati) directed to the Cys12 amino acid residue of the active center have achieved significant clinical responses in NSCLC [30,31].